NY-CITCO-GROUP-OF-COMP
30.5.2019 18:05:10 CEST | Business Wire | Press release
The Citco Group of Companies, (“Citco”), a leading provider of asset servicing solutions to the global alternative investment industry, today announced a product partnership with S3 Partners, a leading fintech innovator and data analytics firm, and the integration of its BLACKLIGHT Treasury Management solution.
S3 Partners’ real-time, independent financing data prices opaque borrow and loan markets and redefines short interest, crowding and previously stale indicators for which the industry has had no centralized source. BLACKLIGHT leverages these analytics along with leading technology for better outcomes in investment process, risk management, and counterparty relationships.
The agreement between Citco and S3 allows Citco clients to get the benefit of BLACKLIGHT’s Financing Trade Cost Analytics (FinTCA) tools to maximize trade, margin and collateral exposures and efficiencies. The platform will be rolled out via Citco’s Æxeo Treasury platform.
“Our focus at Citco has always been to provide our clients with the best technologies and services to make their lives easier. This is why we have decided to integrate S3’s market-standard BLACKLIGHT suite of data and technology,” said Albert Bauer, Managing Director at Citco Fund Services (USA) Inc. “Integrating BLACKLIGHT into our existing Citco framework enables us to provide S3’s efficient insights to best execution, cost of margin and working capital and to monitor liquidity alongside our new Æxeo Treasury platform. Our clients have asked for these nuanced analytics which we can now offer via BLACKLIGHT with single-sign-on access and virtually no operational friction.”
“We are thrilled that Citco has chosen to partner with us and recognizes the value of our broker-neutral solutions,” said Bob Sloan, Founder of S3 Partners. “The Citco-S3 alliance, along with our distribution via Bloomberg, Nasdaq and Reuters, expands the reach of our technology and data to every player type and client segment.”
About Citco Group of Companies
The Citco Group of Companies (Citco) is a leading provider of asset servicing solutions to the global alternative investment industry. With over $1 trillion in assets under administration and 6,500 staff deployed across 40 countries, Citco’s unique culture of innovation and client-driven solutions has provided Citco’s clients with a trusted partner for more than four decades. Having grown organically into one of the largest asset servicers in the industry, Citco’s Fund Services division offers a full suite of middle office and back office services including, treasury and loan handling, daily NAV calculations and investor services, corporate and legal services, regulatory and risk reporting as well as tax and financial reporting services. Investing heavily in innovation and technology whilst further developing its current suite of client friendly solutions, Citco will continue as a flagbearer for the asset servicing industry. For more information, go to www.Citco.com .
About S3 Partners
Founded in 2003, S3 Partners is a financial technology and data company. Clients use our technology and data for better outcomes in their investment process, risk management, counterparty relationships, and investor relations. Like any resource, the integrity and purity of data is defined by how it’s sourced, how and why it’s filtered, who can access it, and how it’s interpreted. Data is only potential until you find a way to refine it. Refining data potential into financial power is S3’s business. Our suite of tools arms you to not just access data but to wield it; cut through marketplace opacity and see with clarity where opportunity lies for your business, portfolio, and the entire market. S3’s comprehensive data integrity powers your market perception and business intelligence so you can act with agility, on your own terms. For more information about S3 Partners, please visit s3partners.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190530005653/en/
Contact:
For Citco New York Hannah Beard | +1 646 274 1421 London Aryna Kastavetskaya | +44 20 3040 0871 citco@peregrinecommunications.com For S3 Partners ASC Advisors Steve Bruce / Taylor Ingraham sbruce@ascadvisors.com / tingraham@ascadvisors.com 203-992-1230
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom